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Ion-coupled transporters must regulate access of ions and
substrates into and out of the binding site to actively transport
substrates andminimize dissipative leak of ions.Within the sin-
gle-site alternating accessmodel, competitive substrate binding
forms the foundation of ion-coupled antiport. Strict competi-
tionbetween substrates leads to stoichiometric antiportwithout
slippage. However, recent NMR studies of the bacterial multi-
drug transporter EmrE have demonstrated that this multidrug
transporter can simultaneously bind drug and proton, which
will affect the transport stoichiometry and efficiency of coupled
antiport. Here, we investigated the nature of substrate competi-
tion in EmrE usingmultiple methods to measure proton release
upon the additionof saturating concentrations of drug as a func-
tion of pH. The resulting proton-release profile confirmed
simultaneous binding of drug and proton, but suggested that a
residue outside EmrE’s Glu-14 binding site may release protons
upon drug binding. Using NMR-monitored pH titrations, we
trace this drug-induced deprotonation event toHis-110, EmrE’s
C-terminal residue. Further NMR experiments disclosed that
the C-terminal tail is strongly coupled to EmrE’s drug-binding
domain. Consideration of our results alongside those from pre-
vious studies of EmrE suggests that this conserved tail partici-
pates in secondary gating of EmrE-mediated proton/drug trans-
port, occluding the binding pocket of fully protonated EmrE in
the absence of drug to prevent dissipative proton transport.
Substrate binding and release are critical components of the
mechanistic cycle for ion-coupled transporters. In single-site
alternating access transport, a single binding site is alternately
exposed to either side of the membrane, effectively transport-
ing bound substrate across themembrane. Cooperative binding
between substrate and ion increases the likelihood of cotrans-
port (symport), whereas competition between substrate and
ion favors antiport. Pure exchange of substrate and ion results
when two conditions aremet: 1) if binding of substrate excludes
stable binding of the ion and vice versa and 2) if alternating
access of the transporter is only permitted when substrate or
ion is bound (see Fig. 1, left). This simple, attractive model ele-
gantly explains stoichiometric antiport of ion and substrate and
excludes alternative pathways that would result in dissipative
leak of the driving ion (1, 2). However, the inherent difficulty in
performing biochemistry and structural biology on membrane
proteins has limited our ability to rigorously test the assump-
tions of the pure exchangemodel with a variety of transporters.
Our recent studies of the small multidrug resistance trans-
porter EmrE show that this drug/proton antiporter can simul-
taneous bind both substrates, violating the simplifying assump-
tions of the pure exchange model.
EmrE effluxes a wide range of aromatic cation antibiotics
using the proton motive force across the inner membrane of
Escherichia coli, thus conferring resistance to antibiotics
matching this chemical profile (3). EmrE performs antiport of
drug and proton through a classic single-site alternating access
mechanism (4). The common binding site for drug and proton
is defined by a pair of glutamates (Glu-14; one from eachmono-
mer within the homodimer; see Fig. 2) located deep within the
membrane (5, 6). This binding site is alternately exposed to the
cytoplasm and periplasm through conformational exchange of
EmrE during the transport cycle (5, 7). EmrE’s ease of purifica-
tion, broad substrate specificity, and antiparallel topology have
led to its adoption as a model system for studying multidrug
efflux, membrane protein evolution, and secondary active
transport (8–10). In addition to facilitating genetic analysis,
EmrE’s small sizemakes it an ideal candidate forNMR, allowing
unprecedented structure-function investigations of an ion-
coupled transporter. NMR has been used to confirm EmrE’s
antiparallel topology (11, 12), measure the rates of conforma-
tional exchange (alternating access) (13), probe the effects of
drug or proton binding on EmrE’s structure and dynamics (14,
15), and determine pKa values for bothGlu-14 residues (16, 17).
Through these studies, it has become clear that EmrE’s trans-
port cycle is populated bymore states than are included in pure
exchange antiport.
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Recently, we proposed a new “free exchange” kinetic model
for coupled proton/drug transport by EmrE that includes all
experimentally observed states and transitions of the trans-
porter (Fig. 1, right) (17). In this model, there aremultiple path-
ways around the transport cycle leading to different possible
transport stoichiometries, including symport, antiport, and
uniport of both drug and proton. Nevertheless, EmrE does not
allow rapid proton leak in the absence of drug (17). Further-
more, binding of proton and drug to the single site is competi-
tive: drug binding to one Glu-14 lowers the proton affinity
(pKa) of the second Glu-14, promoting proton release (17),
whereas protonation of the second Glu-14 lowers the drug
affinity (raises the KD) of the first Glu-14, promoting drug
release (17, 18). This competition is critical for ensuring that
proton/drug antiport is the dominant transport process for
commonEmrE substrates under physiological conditions, lead-
ing to its well-established function as a proton-coupled drug
efflux pump (19). Here, we further investigated this important
competition between drug and protons by examining drug-in-
duced proton release fromEmrE. The results are generally con-
sistent with the free exchange model but suggest that an addi-
tional residuemay release protons upon drug binding.We trace
this deprotonation event toHis-110, EmrE’sC-terminal residue
and the only residue other thanGlu-14 that has a pKa value near
neutral pH (16).
High-resolution structures of EmrE in different states of the
transport cycle would shed light on the coupling mechanism
between substrate binding and transport. However, the confor-
mational plasticity that enables EmrE to transport diverse sub-
strates also makes it a very challenging system for high-resolu-
tion structural studies (15, 20). As a result, there are currently
only low-resolution cryo-EM (21, 22) and X-ray structures
available (23) for the antiparallel EmrE homodimer (Fig. 2). The
one region of EmrE that is not visible in these structures is the
C-terminal tail. Terminal regions of proteins are frequently
missing fromcrystal structures due to their dynamic nature and
lack of regular structure. However, the NMR spectra of EmrE
reveal that the C-terminal region of EmrE is not just a floppy
tail. The residues in this region, including 105–110, have very
unique chemical shifts that are not typical of-helix or random
coil, and the peaks are not as intense as they would be in an
unstructured tail (11, 14). In addition, residues in this tail are
sensitive to the occupancy of the binding pocket, with signifi-
cant chemical shift perturbations upon protonation or drug
binding (Fig. S1) (14). Finally, His-110 is highly conserved (Fig.
S2) (24–26), indicating that it may be functionally important.
Here, we show that the C-terminal tail of EmrE is strongly cou-
pled to the binding domain, suggesting a potential role in sec-
ondary gating of EmrE transport.
Results
Modeling drug-induced proton release
Because drug and proton compete for binding to EmrE, addi-
tion of drug to EmrE triggers the release of protons fromGlu-14
that can be directly measured with a pH electrode in a weakly
buffered environment. In an earlier study, addition of a con-
stant, low concentration of tetraphenylphosphonium (TPP)4
to EmrE across a range of pH values produced a bell-shaped
proton-release profile (27). This provided experimental confir-
mation of competitive binding between drug and proton for the
first time in a solubilized transporter. However, these experi-
mental conditions cannot distinguish between pure exchange
and free exchange models. This is because drug and proton
compete for binding to Glu-14 in both models, consistent with
a weaker KDapp for TPP binding to EmrE at low pH when pro-
ton concentration is high (5, 17). Thus, addition of a low con-
centration of drug will not be sufficient to compete with and
trigger release of protons from EmrE at low pH under either
model.
If sufficient drug is added to saturate EmrE at all pH condi-
tions, then the number of protons released upon drug binding
to EmrE as a function of pH has a very different profile for the
pure exchange and free exchange models (Fig. 3). Because the
pure exchangemodel forbids simultaneous binding of drug and
proton, any protons bound to the EmrE dimer initially will be
released upon addition of a saturating concentration of drug.
Thus, the number of protons released per EmrE dimer is simply
the fraction of EmrE protonated in the drug-free state at the
start of the experiment.
4 The abbreviations used are: TPP, tetraphenylphosphonium; ITC, isother-
mal titration calorimetry; TM, transmembrane helix; TROSY, transverse
relaxation optimized spectroscopy; HSQC, heteronuclear single-quantum
coherence; HMBC, heteronuclear multiple bond correlation spectroscopy;
SMR, small multidrug resistance; MD,molecular dynamics; DMPC, dimyris-
toylphosphatidylcholine; DLPC, dilauroylphosphatidylcholine; DHPC,
dihexanoylphosphatidylcholine; Bicine, N,N-bis(2-hydroxyethyl)glycine;
TCEP, tris(2-carboxyethyl)phosphine; BES, 2-[bis(2-hydroxyethyl)amino]
ethanesulfonic acid.
Figure 1. Two competing models for antiport. In pure exchange (left), strict competition for the single site between drug and two protons, along with
prohibition of alternating access in the absence of substrate or ion, leads to tightly coupled stoichiometric antiport of 2H/drug. In free exchange, competition
remains, but no restrictions are placed on binding or alternating access, allowing both 1H/drug (orange) and 2H/drug (red) antiport.
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We assume cooperative proton binding reflected by a single
pKa of 7.3, in agreementwith previous studies suggesting a pure
exchange mechanism with a single pKa for drug-free EmrE (13,
18, 28). Allowing asymmetric protonation of drug-free EmrE
with two pKa values for Glu-14, as shown by NMR (16), simply
decreases the slope of the curve for proton release as a function
of pH. In either case, at low pH where EmrE is fully protonated
in the absence of drug, addition of a saturating drug concentra-
tion leads to the release of two protons (Fig. 3A, black).
For the free exchangemodel, the number of protons released
upon drug binding can be calculated from the difference in
Glu-14 protonation states in the presence and absence of drug.
protons released 2EH2 EH
 EDH (Eq. 2)
The net protonation state of EmrE in each condition is read-
ily calculated using the Glu-14 pKa values (Table 1 and Equa-
tions 3–5). These pKa values were determined from NMR pH
titrations of drug-free EmrE at 25 and 45 °C (16), TPP-bound



















At low pH, the free exchange model allows simultaneous
binding of one drug and one proton, so only one proton will be
released (Fig. 3A, blue and red) instead of the two protons pre-
dicted by the pure exchange model. To experimentally distin-
guish these two models, we first needed to establish the TPP
concentration necessary to saturate EmrE across the entire pH
range.
Determination of pH-dependent TPP binding affinity
Weused isothermal titration calorimetry (ITC) to determine
the KDapp for TPP binding to EmrE solubilized in isotropic
bicelles at pH 5.5, 6.5, 7.5, or 8.5 and 45 °C. The titration profile
observed at pH5.5with ITCdirectly confirms that saturation of
the binding site with TPP can be achieved even at low pH.
Furthermore, the ITC data confirm that one drug binds per
asymmetric dimer at all pH values (Table S1) as expected for
TPP binding to the single site defined by Glu-14 in EmrE (30).
Using these experimentally determined KDapp values, we calcu-
lated the concentration of TPP needed to bind at least 99% of
EmrE present in the proton-release assay at each pH value.
Measurement of proton release by ITC
In addition to the thermodynamics of drug binding, ITC can
provide an indirect but robust measurement of proton release
(31–33). The enthalpy observed upon drug binding (Hobs0 )
includes both the heat of reaction for protein–drug binding and
consequent proton release as well as the enthalpy change due to
released protons binding to the buffer. By measuring the stan-
dard enthalpy change (Hobs0 ) upon drug binding in multiple
buffers with varying heats of ionization (Hbi ), the number of
protons released upon drug binding can be determined from
the slope of Hbi versus Hobs0 as described in detail previously
(17).
Wemeasured Hobs0 of TPP binding to EmrE solubilized in
isotropic bicelles from pH 5.5–8.5 at 45 °C using at least three
buffers at each pH (Table S1 and Fig. 3, C and E). If drug and
proton binding were exclusive, as predicted by pure exchange,
we would expect to see the release of two protons per dimer at
low pH. Instead, slightly more than one proton is released per
dimer at pH 5.5 in agreement with our previous experimental
observation that EmrE can simultaneously bind drug and pro-
ton. However, the data are not perfectly consistent with the free
exchangemodel:more protons are released than predicted near
neutral pH (Fig. 3A, red). The free exchange model considers
only Glu-14 protonation and deprotonation events as previous
mutagenesis studies only implicated Glu-14 in drug and proton
binding by EmrE (5, 6, 27), and Glu-14 is the only protonatable
residue within the transmembrane helices that define the sub-
strate-binding pore in EmrE (Fig. 2). Before considering the
possibility that another residue may also participate in coupled
binding/release of drug and protons, we first confirmed our
experimental observation that the number of protons released
uponTPPbinding is inconsistentwith anGlu-14–onlymodel
Figure2. StructureofTPP-boundEmrE.The crystal structure (ProteinDataBank code3B5D) (23)withmonomerA inmagenta,monomerB inblue, andTPP
inorange is shown. TheCofGlu-14 is shownasagreen sphere. The final residue in the structure, Ser-105A, is indicatedbya reddot. The locationof theC-terminal
tail is unknown, but it could interact with positively charged residues in the monomer B loops (dotted line) or fold into the binding pocket itself (dashed line).
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using a different experimental approach and at a lower temper-
ature (25 °C).
Direct measurement of drug-induced proton release
In the original investigation of drug-induced proton release
(27), 4 M aliquots of TPP were added to weakly buffered
EmrE solubilized in detergent, and pH changesweremonitored
and quantified directly using an electrode. We repeated this
experiment using EmrE solubilized in bicelles and with 5 mM
TPP (Fig. 3, B and D), a concentration sufficient to saturate
EmrE at all pH values based on our ITC experiments at 45 °C.
We have previously shown that KDapp decreases with tempera-
ture (11). Thus, this TPP concentration will also be sufficient
to saturate EmrE at 25 °C where the drug binds more tightly.
Upon monitoring proton release in this manner, we again
found that EmrE releases around one proton per dimer at low
pH but releases more protons than expected near neutral pH
(Fig. 3A, blue). When considered alongside the ITC experi-
ments, this strongly suggests that a second residue, other than
Glu-14, releases protons upon binding of drug to EmrE.
Which other residue could be involved in the coupled bind-
ing and release of drug and protons? The previous investigation
of drug-induced proton release considered Glu-25 and Asp-84
(27) and found that they do not contribute to proton release.
Figure 3. Glu-14 alone cannot account for drug-induced proton release. A, proton release per EmrE dimer upon addition of saturating concentration of
TPP as predicted by pure exchange (black line) or free exchange models of transport at 25 (blue line) or 45 °C (red line), assuming Glu-14 is the only residue
involved. Experimental proton release, whethermeasured directly at 25 °C (blue circles) or by ITC at 45 °C (red circles), ismore consistentwith the free exchange
model at low pH where the two models are most distinct. However, more protons are released upon TPP binding near neutral pH than would be predicted
by the Glu-14–only free exchange model. Error bars indicate the S.E. of the fit of proton release at each pH value. B, fit of proton release measured directly at
25 °C and pH 6 by pH electrode as a function of EmrE concentration. The slope indicates the drug-induced proton release per dimer (sample data shown inD),
and the error bars indicate the S.D. of standardHCl aliquots.C, fit of enthalpy of TPPbinding as a function of buffer ionization enthalpy at 45 °C andpH7.5. The
negative slope represents the proton release per monomer (sample data shown in E). Error bars indicate the S.E. in the fit of Hbinding. D, representative trace
of TPP-induced proton release at pH 6. At the indicated time point, 5 mol of TPP was added to a solution containing 7.5 nmol of EmrE dimer, causing a
release in protons seen by the drop in pH. This pH dropwas converted to nmol of H by the subsequent addition of known quantities of NaOH and HCl to the
solution. Additional aliquots of HCl and NaOHwere added to improve quantitation (data not shown). E, overlay of representative ITC binding curves for TPP
at 45 °C and pH 7.5 in either potassium phosphate (gray), BES (dark blue), MOPS (beige), imidazole (brown), or Tris (light blue) buffer (see Table S1 for complete
ITC data).
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This is consistent with our more recent NMR-monitored pH
titration experiments, which do not show any titration of
Asp-25 or Glu-84 near physiological pH. Instead, the only res-
idue other than Glu-14 that titrates near neutral pH in our
NMR experiments is His-110 (16), which has not been previ-
ously considered in the proton-release mechanism. This
C-terminal residue is highly conserved among EmrE-like
members of the SMR family (Fig. S2) but has no known role
in EmrE function. Could His-110 account for the elevated
proton release?
Determination of His-110 pKa
To test this hypothesis, we performed pH titrations of drug-
free and TPP-bound EmrE using 1H-15NHMBCNMR exper-
iments to directly observe the histidine side chain (Fig. S5) (34).
Although HMBC experiments are relatively insensitive, the
direct observation of the imidazole ring enables an accurate
determination of the histidine side chain pKa value. Conve-
niently, EmrE only has a single histidine residue, allowing clean
observation of His-110 in this experiment.
At 45 °C, the rapid rate of alternating access in drug-free
EmrE results in intermediate or fast exchange of the His-110A
and His-110B peaks such that they are not resolved in the
HMBC spectra, preventing accurate determination of the His-
110 side chain pKa values at that temperature. Fortunately, at
25 °C, the peaks corresponding toHis-110 from eachmonomer
in the asymmetric homodimer are clearly resolved (Fig. 4 and
Figs. S5, S6, and S7), allowing the determination of the pKa for
His-110A and His-110B separately (Table 1 and Fig. 5). This
reveals a drug-induced pKa shift of His-110A (Table 1), which is
in the C-terminal tail of EmrE located on the open side of the
transporter. Interestingly, there is no drug-induced pKa shift
for His-110B, which is located on the closed face. The pKa shift
of His-110A upon TPP binding will result in the release of
protons from this C-terminal residue. Including proton release
from His-110 along with the proton release from Glu-14 in the
free exchange model gives a better fit of the experimental pro-
ton-release data at 25 °C (Fig. 6).
Evidence for coupling of the C-terminal tail to the binding
pocket
The drug-induced pKa shift of His-110A (Table 1) and sensi-
tivity of the C-terminal tail chemical shifts to the identity of the
bound substrate (Fig. S1) could occur through direct interac-
tion with the binding pocket or indirectly due to large-scale
conformational change upon drug binding. To investigate this
further, we reanalyzed the effect of pH on the backbone amide
groups throughout EmrE as recorded in the 1H-15N TROSY-
HSQC pH titration of TPP-bound EmrE (Fig. S3). We have
previously shown that pH-dependent chemical shift perturba-
tions of core residues in the binding pocket of drug-bound
EmrE are the result of protonation of Glu-14 (16). As expected,
residues in the tail of monomer B have pH-dependent chemical
shift perturbations that are well-fit with a pKa value matching
the His-110B side chain pKa value (Table 1 and Fig. S4). How-
ever, thepH-dependent chemical shifts of residues in themono-
mer A C-terminal tail have pKa values that match the pKa of
Glu-14, not His-110A. This strong coupling between the C-ter-
minal tail of monomer A and Glu-14 suggests a more direct
interaction of this tail with the core binding domain of EmrE,
either with the binding pocket itself or with the structured
loops surrounding the pocket (Fig. 2).
Assessing solvent accessibility of His-110
If the C-terminal tail of monomer A is interacting with the
binding pocket in some way, it may be protected from water
because the binding cavity is hydrophobic and poorly hydrated
relative to the bulk aqueous solution (35). To analyze the sol-
vent accessibility of the C terminus, we recorded spectra with
and without a water-soluble paramagnetic ion, Mn2 (Fig. 7).
The Mn2 will cause paramagnetic relaxation enhancement of
nearby nuclei, leading to the disappearance of peaks in the
NMR spectra that correspond to residues accessible to water.
At high pH, the backbone amides of both His-110A and His-
110B are in an aqueous environment because these peaks dis-
appear in the presence of Mn2. However, at pH 5.2, the His-
110 signals remain visible in the spectrum even in the presence
of Mn2, indicating that His-110 is more protected from water
at low pH (Fig. 7).
Evidence for a second state of His-110A
At elevated pH, the His-110A peaks are broadened in the
nitrogen dimension, indicative of microsecond to millisecond
transitions between different conformational states. This is
apparent to a certain extent for drug-free EmrE and is even
more pronouncedwith TPP bound. Although no second state
is visible in the HMBC spectra, this pulse sequence is relatively
insensitive and may not detect lowly populated states. To
address this, we prepared TPP-bound EmrE selectively
labeled with [13C,15N]histidine and acquired TROSY-HSQC
spectra at pH 6 and 8 to observe the backbone amides. Because
His-110 is the only histidine in EmrE, only peaks corresponding
to His-110 are visible. The increased sensitivity of this pulse
sequence reveals two peaks in addition to the major states of
His-110, confirming that His-110 has multiple conformations
when TPP is bound (Fig. 8). It likely that His-110 also exists in
multiple conformations for drug-free EmrE, but the highly
Table 1
pKa values for Glu-14 and His-110 determined by NMR
Residue Drug-free TPP-bound
25 °C
Glu-14a 6.8 0.1 (16) 6.32 0.02b
Glu-14a 8.5 0.2 (16)
His-110A 7.05 0.02c 6.77 0.03c
His-110B 6.98 0.01c 6.97 0.03c
C-terminal tail A N/Ad 6.34 0.04b
C-terminal tail B N/A 7.00 0.04b
45 °C
Glu-14a 7.0 0.1 (16) 6.8 0.1 (17)
Glu-14a 8.2 0.3 (16)
a Drug-free EmrE pKa values are macroscopic pKa values and cannot be unambig-
uously assigned to Glu-14A or Glu-14B. The pKa value for TPP-bound EmrE is
due to protonation of Glu-14B.
b Determined by TROSY-HSQC monitoring backbone amide chemical shift
change with pH (Figs. S3 and S4). For the C-terminal tail, chemical shift pertur-
bations of Ser-105, Arg-106, and Thr-108 fit to the reported pKa values (Fig. S4).
cHis-110 pKa value of the side chain imidazole determined from a pH titration
with HMBC NMR spectra (Fig. 5 and Figs. S6 and S7).
dN/A, not applicable.
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dynamic nature of EmrE under these conditions makes this
difficult to demonstrate conclusively.
Discussion
Ion-coupled transport requires regulated access of ions and
substrates into and out of the binding site. Transport will be
biased toward symport or antiport depending on whether ion
and substrate binding is competitive or cooperative and how
the relative rates of alternating access vary when the trans-
porter is empty or bound to substrate and/or ion.Cartoonmod-
els of transporters often exclude states and transitions that
would weaken coupling efficiency or lead to leak pathways, but
few transporters have been studied in sufficient detail to unam-
biguously support their exclusion. Recently, it was shown that
the H/sugar symporter GlcP is capable of H/sugar antiport
in violation of traditional models of symport (36). Instead, the
authors proposed a “universal” kinetic model of transport that
can accommodate symport, antiport, or uniport depending on
the rates of the transitions between the various states. This is
similar to our free exchange model for EmrE. In the case of
EmrE, the rates of alternating access in different substrate-
bound and substrate-free states have previously been studied
(13–17, 35) and do not follow the expected patterns for coupled
antiport. Both NMR experiments andMD simulations indicate
that apoEmrE is capable of alternating access (13, 16, 35), and
NMR demonstrates that EmrE can simultaneously bind and
transport drug and proton near neutral pH (17). Those results
suggest that EmrE should be capable of both symport and anti-
port of drug and protons and should rapidly leak protons. Nev-
ertheless, functional assays demonstrate that EmrE does not
leak protons in the absence of drug. Furthermore, although
liposomal transport assays indicate that EmrE may be capable
of both symport and antiport, its well-established drug-resis-
tance activity indicates that antiport is the dominant func-
tion under physiological conditions (17). Here, we focus
on the competition between drug and proton binding to
EmrE to see whether this matches the expectations for an
ion-coupled antiporter.
The experiments presented here investigated the competi-
tive binding of drug and protons to EmrE to better understand
how this promiscuous transporter is biased toward net anti-
port. We have identified an additional protonatable residue
coupled to drug binding, His-110, and demonstrate that the
C-terminal tail of EmrE on the open side of the transporter is
strongly coupled to the Glu-14 binding pocket within TM1–3.
At first, a role for His-110 in EmrE’s binding mechanism seems
surprising. The C-terminal tail of EmrE extends from TM4,
which mediates EmrE dimerization and is set apart from EmrE’s
core binding domain (TM1–3) (Fig. 2) (25). Previous Cys-scan-
ning mutagenesis studies of EmrE did not reveal a significant role
for theC-terminal tail in substrate binding or transport (6, 37, 38).
However, His-110 is highly conserved across the SMR family (Fig.
S2), suggesting an important but as yet undiscovered functional
role. Consideration of our results alongside previous studies of
EmrE suggests that this conserved tail may participate in second-
ary gating of EmrE transport, occluding the binding pocket of fully
protonated EmrE in the absence of drug and preventing proton
leak.
Figure4.NMR-monitoredpHtitrationofHis-110sidechain.A, His-110peaks for eachmonomer inHMBCNMRspectraofdrug-freeEmrE in isotropicbicelles
are clearly resolved at 25 °C. Three or four peaks are observed for each imidazole ring as explained in Fig. S5. As pH changes, the peak positions titrate along a
line, consistentwith a single protonation event. The peak positions at lowpH fall along this line for bothmonomers, indicating that the peak overlap at lowpH
is due to similar chemical environments for the two residues, not fast exchange. Thus, thepKa for eachmonomer canbedetermined separately. Representative
peaks are shown (see Fig. S6 for full titration). B, during alternating access conformational exchange, EmrE’s antiparallel protomers swap conformation.
Monomer A is defined as the protomer in which the N and C termini (His-110A) are facing the same side of themembrane as the binding pocket regardless of
whether EmrE is open-up or open-down.
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To better understand the functional implications of compe-
tition between drug and proton binding to EmrE, we measured
drug-induced proton release from EmrE as a function of pH
(Fig. 3). At low pH, we observed the release of approximately
one proton per dimer, which is consistent with the simultane-
ous binding of drug and proton by EmrE and the free exchange
model. Surprisingly, around neutral pH, we observed greater
proton release than could be explained by consideration of drug
and proton binding at the established “single” binding site
defined by Glu-14. Our prior NMR-monitored pH titrations
showed that His-110 is the only other residue that titrates near
neutral pH (16). We observed a drug-induced pKa shift for the
imidazole side chain ofHis-110A in the presence and absence of
TPP. Incorporating the proton release from His-110 into the
model accounts for the increased proton release near neutral
pH.
In addition to the drug-induced pKa shift of His-110, the C
terminus of EmrE is acutely sensitive to drug binding. These
effects could be due to direct interaction of the C-terminal tail
with the binding site near Glu-14 or indirectly through changes
in the overall conformation when EmrE is bound to different
drugs. The tail is not resolved in the available crystal and
cryo-EM structures of EmrE (21, 23), preventing a direct struc-
tural analysis. Re-examination of our previous NMR pH titra-
tions monitoring the backbone amides (Fig. S3) revealed that
the backbone amides in tail A fit to a pKa of 6.3, matching the
pKa of Glu-14 in the active site of TPP-bound EmrE (Table 1).
The large pH-dependent chemical shifts displayed by these res-
idues indicate a significant change in chemical environment,
which could be consistent with a direct interaction with the
binding domain. The poor solvent accessibility of His-110 at
low pH for TPP-bound EmrE further indicates that the tail is
located in a less exposed environment as would be the case if it
folds back toward the active site (Fig. 2, dashed line). Interest-
ingly, in a recent molecular dynamics study using a complete
model of EmrE embedded in a lipid bilayer, the tail ofmonomer
A existed in heterogeneous populations, some of which did
extend back into the binding pocket for an extended period
during the simulation (35). Our experimental results, including
our observation of multiple states for His-110, are consistent
with this MD simulation.
Figure 5. Determination of the His-110 side chain pKa. A, the H
2 and N2 chemical shifts of His-110A (filled) and His-110B (open) from the HMBC pH titration
of drug-free EmrE are fit to determine the pKa. H
2 and N2 data were simultaneously fit to a single pKa for eachmonomer individually. B, fit of His-110
A (filled)
and His-110B (open) from the HMBC pH titration of TPP-bound EmrE. Proton and nitrogenwere fit together, but due to line broadening at high pH, there are
nonitrogendata abovepH7.77 forHis-110A. A summary of pKa values canbe found in Table 1. Error bars indicate thepeakwidth at half themaximum intensity.
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If the C-terminal tail can extend into the binding pocket,
what is its role in the transport mechanism of EmrE? A possible
functional mechanism for the C-terminal tail as a secondary
gate in EmrE begins to emerge from consideration of our
data and previously published experiments examining the
structure and function of EmrE using a variety of experimen-
tal approaches.
In recentMD simulations, the binding pocket spontaneously
dehydrated when both Glu-14 residues were protonated (35).
This is in agreement with double electron–electron resonance
EPR measurements, which showed repacking of the TM3-4
loop to occlude the binding pocket upon lowering the pH from
8 to 5 for drug-free EmrE (28). Interestingly, this pH-dependent
conformational changewas also observed in E14Q-EmrE, dem-
onstrating that it must depend on the protonation of a residue
other than Glu-14. The authors proposed protonation of
Glu-25 and Asp-84 given the locations of these residues within
the structure and the effect of mutations at these positions.
Although this is a logical conclusion, there is no evidence for
protonation of either Glu-25 or Asp-84 in this pH range in our
NMR spectra, which provide a more direct probe of electro-
static environments (16). However, as shown here, His-110
does titrate in this pH range and is sensitive to drug binding.
Additionally, both coevolutionary analysis andMD simulations
suggest interactions between the C-terminal tail and the
TM3-4 loop (Fig. S8). Furthermore, in the MD simulations,
interactions were observed between His-110A and the TM1-2
loop where Glu-25 is located. These interactions only occurred
when EmrE was fully protonated or in an unstable singly pro-
tonated state that is likely physiologically irrelevant.
In consideration of these results, we propose that protona-
tion of His-110A at low pH could facilitate electrostatic inter-
actions between positive charges in theC-terminal tail (His-110
and Arg-106) and the negatively charged Glu-25 and Asp-84 in
the TM1-2 and TM3-4 loops (Fig. 2, dotted line). Formation of
such an interaction upon His-110A protonation could explain
the pH-dependent conformational change of the TM3-4 loop
to occlude the Glu-14 binding pocket observed by EPR at low
pH and is consistent with the NMR pH titration data and evo-
lutionary couplings. If the binding pocket is occluded when
EmrE is fully protonated, it would prevent proton transport
across themembrane in the absence of drug. This could explain
the most significant shortcoming of the Glu-14-only free
exchangemodel, the prediction that EmrE should rapidly trans-
port protons across the membrane in the absence of drug in
contrast to results from proton leakage assays that show no
significant proton leak (17).
However, for EmrE to perform coupled antiport of drug and
proton, proton transportmust occur in the presence of drug. In
an early NMR study of EmrE, TPP binding to EmrE wasmon-
itored by 31PNMR, allowing direct observation of the drug (40).
In that study, two distinct populations of EmrE-bound TPP
were observed. At low concentrations, TPP bound weakly to
Glu-25 and Asp-84 via electrostatic interactions. Binding of
TPP to the canonical binding site at Glu-14 only occurred
when the TPP:EmrE dimer ratio exceeded 1:1 even though
this site has a higher affinity. We propose that the binding of
TPP to Glu-25 and Asp-84 observed at low drug concentra-
tions (40) disrupts the electrostatic interactions between these
residues and the positively charged C-terminal tail. This results
in release of the C-terminal tail from interaction with the loops
surrounding the transport, opening the secondary gate and
allowing proton release fromanddrug binding toGlu-14within
the transport pore. Although speculative, this mechanism is
consistent with the experimentally observed behavior of the
loop and the tail of EmrE and would explain the tight kinetic
correlation of drug on-rates and proton off-rates previously
observed by stopped flow (18). Our proposed model is also
analogous to a recently uncovered mechanism inMdfA, a mul-
tidrug/proton antiporter from themajor facilitator superfamily
with a remarkably similar substrate profile to EmrE in which
electrostatic interactions between loop residues around the rim
of the binding pocket are essential to proper gating of transport
(41).
Although gating is a common feature of transporters (2, 42),
the presence of a secondary gate in EmrE would be remarkable
in a such a small transporter. At first glance, distinctions
between secondary gating within a free exchange transport
model and the pure exchange model of antiport might seem
trivial because both mechanisms are gated, limiting proton
transport in the absence of drug. However, gating EmrE at the
fully protonated state, as proposed here, rather than the depro-
tonated state is a crucial distinction. In the pure exchange
model, proton leak is prevented by stipulating that the empty
transporter cannot alternate access. If EmrE can alternate
access when deprotonated, as demonstrated by NMR (15, 16)
and allowed in the free exchange model, then EmrE should
confer drug sensitivity under certain conditions. Indeed, EmrE-
mediated sensitivity to methyl viologen, a 2 substrate, has
been demonstrated both at high pH (19) and at neutral pH
when the Glu-14 pKa is lowered by mutation to aspartate (13).
This is consistent with electrogenic drug uptake. Additionally,
Figure 6. His-110 contributes to drug-induced proton release at 25 °C.
Predicted proton release due to the drug-induced pKa shift of Glu-14 (dashed
line) or His-110 (dotted line) measured by NMR is shown. Including both
Glu-14 and His-110 in the proton-releasemodel (solid line) leads to increased
proton release near neutral pH and gives a better fit of the data compared
with an Glu-14–only model (dashed line). Error bars indicate the S.E. of the fit
of proton release at each pH value.
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this mechanism would explain the ease with which EmrE can be
transformed from a proton-coupled efflux pump to a polyamine
importer by a single pointmutation,W63G (43). Such amutation
would not need to fundamentally alter the dynamics or mecha-
nism of the transporter; it would merely need to change EmrE’s
binding specificity. Finally, this mechanism would represent an
inversionof the strict competition stipulatedby thepure exchange
model.Rather thanexcludingsimultaneousdrugandprotonbind-
ing, binding of drug, albeit to a secondary site, would be required
forproton release.Competitionbetweendrugandproton remains
central to antiport, but themechanismmay be very different from
mechanisms proposed by earlier models.
Experimental procedures
Expression and purification
EmrE was expressed and purified as described previously
(44). 15N-Labeled samples were grown in M9 medium supple-
mentedwith 1g/liter 15NH4Cl (forHMBCexperiments) orD2O
M9 medium supplemented with 0.5g/liter 15N ISOGRO (Sig-
ma-ISOTEC) and 1g/liter 15NH4Cl (for HSQC experiments).
Histidine-labeled samples were grown in M9 medium with 33
mg/liter 13C,15N-labeled histidine added 1 h prior to induction.
EmrE purified in n-decyl-	-D-maltopyranoside was reconsti-
tuted intoDMPCorDLPC liposomes at a 1:80 EmrEmonomer:
lipid molar ratio. Detergent was removed by Amberlite XAD-2
beads, and liposomes were collected by ultracentrifugation.
Samples were resuspended in NMR buffer containing DHPC at
a 1:3 long chain to short chain lipid ratio to prepare isotropic
bicelles.
Isothermal titration calorimetry
ITC titrationswere performed in aTA Instruments LowVol-
ume Nano calorimeter using the ITCRun software (TA Instru-
ments, Lindon, UT) with 2.5-l injections, stirring at 350 rpm
at 45 °C. Each buffer condition was run two to four times with a
minimum of three buffers per pH value between 5.5 and 8.5. At
lower pH values, samples contained 20 mM buffer and 20 mM
NaCl. At pH8.5, all samples contained 50mMbuffer to improve
buffering capacity and minimize pH drift. Buffer ionization
enthalpies were adjusted to 45 °C using the reported standard
molar heat capacity change at 25 °C (29). Each titration was
analyzed independently, confirming the 1 TPP:EmrE dimer
(n  0.5 TPP/EmrE monomer) binding stoichiometry under
all conditions. ITC experiments in MOPS at pH 7.5 were per-
formed with both 20 and 50 mM MOPS to confirm that
observed binding enthalpies were independent of buffer con-
centration. EmrE in 1:3 DLPC:DHPC isotropic bicelles ranged
in concentration from 25 to 835 M EmrE (monomer concen-
tration), and TPP concentrations varied from 76 M to 5 mM
TPP, depending on pH, to keep the c-value for the ITC exper-
iment in an optimal range. Sample pH was checked at 45 °C
before and after each experiment. Data are reported in Table
S1. The data were fit as described previously (17, 39).
Modeling proton release
Proton release from Glu-14 was modeled as described in the
main text. Proton release from His-110A was similarly calcu-
lated by subtracting the fraction of protonated His-110A in
Figure 7. His-110 is protected from solvent at low pH. TROSY-HSQC NMR spectra of TPP-bound EmrE in the absence (top) and presence (bottom) of the
paramagnetic ionMn2 (0.5mM) are shown. At lowpH, theHis-110 signal is not fully relaxedbyMn2, indicating that it is at least partially protected fromwater
under these conditions.
Figure 8. His-110 exists in multiple states when TPP is bound. TROSY-
HSQC spectra of TPP-bound EmrE selectively labeledwith [13C,15N]histidine
reveal at least two additional histidine peaks at both low and high pH. These
could correspond to two additional states of His-110A or one additional state
each of both His-110A and His-110B.
EmrE’s C-terminal tail is coupled to substrate binding














TPP-saturated EmrE from the fraction of protonated His-
110A in drug-free EmrE where




using the relevant pKa value from Table 1. The pKa values for
His-110B were not significantly different, so no protons are
released from His-110B.
Direct measurement of proton release
EmrE in 1:3 DMPC:DHPC isotropic bicelles with 1 mM
Bicine, 0.5 mM MOPS, 0.5 mM MES, 0.2 mM acetate, 100 mM
NaCl was diluted with bicelles (80 mM DMPC, 240 mM DHPC)
in the same buffer to create stock solutions ranging from 40 to
200 M (monomer concentration) EmrE. 100-l EmrE stock
solutions were diluted with 800 l of 7.5 mM DHPC, 100 mM
NaCl, and precise concentrations were determined from the
A280 (EmrE  38,368 M1 cm1) of this solution immediately
before each experiment. 10mMNaOHorHClwas used to bring
each sample to the desired initial pH. 100 l of 50 mM TPP in
50 mM DHPC, 100 mM NaCl adjusted to the desired pH was
added to saturate EmrE and initiate proton release. Proton
release was monitored directly with a microelectrode using an
HI 2209 analog pH meter from Hanna Instruments digitized
with a DataQ data logger. Proton release was quantified by at
least five subsequent additions of 20 nM HCl and NaOH per
sample, and proton concentration was assumed to be linear
within this range. A minimum of five concentrations of EmrE
was used to monitor proton release at each pH, and a plot of
measured proton release versus dimer concentration was used
to generate reported values of proton release per dimer.
NMR pH titration
All pH titration datawere collected using a BrukerAvance III
HD 900-MHz spectrometer with a cryogenic probe on 0.6–1.0
mM EmrE samples in q 0.33 DMPC:DHPC isotropic bicelles.
Sample buffers contained 100mMBicine, 50mMMOPS, 50mM
MES, 20 mM acetate, 20 mMNaCl, 2 mM TCEP, 6% D2O, 0.05%
NaN3 with 4 mM TPP added to drug-bound samples. Sample
pH was adjusted using a pH electrode and was measured again
after each NMR experiment to account for any pH drift. pH
drifts during 2D NMR experiments were only observed for
titration points above pH 8, and the average pH value was used.
TROSY-HSQC spectra were collected as described previously
(17). HMBC spectra were collected using a modified HSQC
sequence with delays during insensitive nuclei enhanced by
polarization transfer (INEPT) steps adjusted to suppress one-
bond J-coupling and select for long-range coupling. Proton
and nitrogen chemical shifts were fit using IgorPro (Wavem-







where H is the chemical shift of the protonated species at low
pH, D is the chemical shift of the deprotonated species at high
pH, and pKA is the pKa of the titratable group. For drug-bound
HMBC spectra of His-110, broadening of the monomer A peak
in the nitrogen dimension prevented accurate peak position
determination above pH 7.8. Proton peak positions above this
pH were determined from 1D slices of the 2D HMBC spectra.
Paramagnetic relaxation analysis
Four separate uniformly labeled NMR samples were pre-
pared as described in 100 mM MOPS, 100 mM Bicine, 20 mM
acetate, 20 mM NaCl at different pH values. Samples contained
0.7 mM EmrE in q  0.33 isotropic bicelles as well as 0.05%
NaN3, 10%D2O, 2mMTCEP, 2mMTPP, 2mMdisuccinimidyl
suberate. Each sample was adjusted for pH at 35 °C, and the pH
was checked again after data acquisition. To assess paramag-
netic relaxation effects, 0.5 mM MnCl2 was added to each sam-
ple, and another, identical 1H-15N TROSY-HSQC spectrum
was collected in the same manner.
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